osteoporosis
Conditions
Interventions
single administration of teriparatide 56.5 microgram
single administration of normal saline
Sponsors
Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: *Outpatients and inpatients with osteoporosis *Patients with whole PTH less than 100 pg/mL *Any etiologies of kidney disease patients with hemoglobin greater than 10 g/dL *Patients with informed consent
Exclusion criteria
Exclusion criteria: *Patients with asthmatic diathesis and *Patients who develop a rash or symptom of irritation easily *Patients out of the reference ranges of ionized calcium or corrected calcium *Pregnant patients *Patients with severe cardiac or hepatic disease *Patients with dementia or psychiatric disease *Transplant recipients *Patients whose doses or kinds of antihypertensive drug were changed within the previous 2 weeks *Patients with high risk of osteosarcoma *Patients with primary or metastatic bone tumor *Patients who had been treated with teriparatide over 72 weeks *Patients regarded as inappropriate by researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the concentration of 1-34 PTH | — |
Secondary
| Measure | Time frame |
|---|---|
| safety serial trends of bone turnover markers | — |
Countries
Japan
Contacts
Public ContactTakayuki Hamano
Osaka University Graduate School of Medicine Comprehensive Kidney Disease Research
Outcome results
None listed